Navigation Links
Research shows safe dosages of common pain reliever may help prevent conditions related to aging
Date:9/23/2009

HUNTINGTON, W.Va. Recent studies conducted by Dr. Eric Blough and his colleagues at Marshall University have shown that use of the common pain reliever acetaminophen may help prevent age-associated muscle loss and other conditions.

Their study examined how acetaminophen may affect the regulation of protein kinase B (Akt), an enzyme known to play an important role in regulation of cellular survival, proliferation and metabolism.

The researchers' data indicates that aging skeletal muscles experience a decrease in the proper functioning of the enzyme and that acetaminophen intervention in aged animals could be used to restore Akt activity to a level comparable to that seen in young animals. In turn, this improvement in Akt activity was associated with improvements in muscle cell size and decreased muscle cell death.

"Using a model that closely mimics many of the age-associated physiological changes observed in humans, we were able to demonstrate that chronic acetaminophen treatment in a recommended dosage is not only safe but might be beneficial for the treatment of the muscle dysfunction many people experience as they get older," said Blough, an associate professor in the university's Department of Biological Sciences.

The lab's work, which was published in the July 29 issue of the international research journal PLoS One, is the first study to show that acetaminophen ingestion, at least in animals, can be safely used for the treatment of age-related muscle loss. This finding could have far-reaching implications, given the fact that people age 65 and older make up the fastest-growing segment of the U.S. population.

Additional research in their laboratory, which was published in the March issue of the journal Diabetes/Metabolism Research and Reviews, demonstrates the medication may also be useful in diminishing the severity of age-associated hyperglycemia, commonly referred to as high blood sugar.

"It is thought that acetaminophen may exert its action by decreasing the amount of reactive oxygen species," explained Dr. Miaozong Wu, the lead author and a postdoctoral fellow in Blough's lab. "Given the finding that increases in reactive oxygen species may play a role in the development of several age-associated disorders, it is possible that acetaminophen could be used to treat many different types of conditions."

Dr. John Maher, vice president for research and executive director of the Marshall University Research Corporation, said, "These findings are yet another indication that Marshall's researchers are conducting vital research in areas of great importance to human health and safety. I could not be more pleased and wish Dr. Blough and his team continued success."

According to Blough, scientists in his lab will now turn their attention to examining other physiological systems, such as the heart and blood vessels, to see if acetaminophen therapy might have similar benefits for people with cardiovascular disease.


'/>"/>

Contact: Ginny Painter
ginny.painter@marshall.edu
304-746-1964
Marshall University Research Corporation
Source:Eurekalert  

Related medicine news :

1. VA Honors Eye Researchers With Olin Teague Award
2. Private umbilical cord banking not cost-effective, UCSF research shows
3. Neuropathy Association Research Grants Advance the Understanding of Diabetic Neuropathy and Autoimmune Neuropathies
4. Pharmaceutical, Biotech Research Companies Support Newark Rx Assistance Program
5. New research provides new insight into age-related muscle decline
6. Research: People With Type 2 Diabetes Improved Muscular Strength and Exercise Capacity Through Physical Therapist Exercise Counseling Combined With Fitness Center Exercise Training
7. $450,000 Awarded for Innovative Asthma Research Into Death by Drowning in Mucus
8. Juice Newton Performs Benefit Concert to Support Dystonia Research
9. Expert calls for new cancer research priorities
10. California family honors father with second AGA Foundation Research Scholar Award
11. Researchers find drug-eluting stents safe, effective for PCI in diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research shows safe dosages of common pain reliever may help prevent conditions related to aging
(Date:2/12/2016)... ... 12, 2016 , ... Miami Dental Specialists is excited to bring patients the ... Beginning in January, Miami Dental Specialists will offer the non-metal implants as a safe, ... to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... Nearly every health website ... health. These articles generally list between five and 15 foods that should be ... every one of these lists and believes that nutritious eye healthy foods are ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a next ... North America’s leading brand of building products, has improved upon its industry-best array ... mobile version of the ColorView® Exterior Style and Color Selector. Created expressly for ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology: